[EN] HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES [FR] INHIBITEURS DE BIOSYNTHÈSE D'HÉPARANE SULFATE POUR TRAITER DES MALADIES
[EN] HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES [FR] INHIBITEURS DE BIOSYNTHÈSE D'HÉPARANE SULFATE POUR TRAITER DES MALADIES
SYNTHESIS OF CHLORINS AND PHORBINES WITH ENHANCED RED SPECTRAL FEATURES
申请人:Lindsey Jonathan S.
公开号:US20090227553A1
公开(公告)日:2009-09-10
The present invention provides compounds of the general Formula DI: along with methods of making such compounds, formulations containing the same, and methods of using the same (e.g., in photodynamic therapy, for the production of solar cells, etc.)
Synthesis of chlorins and phorbines with enhanced red spectral features
申请人:North Carolina State University
公开号:US08207329B2
公开(公告)日:2012-06-26
The present invention provides compounds of the general Formula DI: along with methods of making such compounds, formulations containing the same, and methods of using the same (e.g., in photodynamic therapy, for the production of solar cells, etc.).
Discovery of isoxazolinone antibacterial agents. Nitrogen as a replacement for the stereogenic center found in oxazolidinone antibacterials
作者:Lawrence B. Snyder、Zhaoxing Meng、Robert Mate、Stanley V. D’Andrea、Anne Marinier、Claude A. Quesnelle、Patrice Gill、Kenneth L. DenBleyker、Joan C. Fung-Tomc、MaryBeth Frosco、Alain Martel、John F. Barrett、Joanne J. Bronson
DOI:10.1016/j.bmcl.2004.06.076
日期:2004.9
A series of potential antimicrobial derivatives possessing bioisosteric replacements for the central oxazolidinone ring found in oxazolidinone antibacterials have been prepared. The design concept involved replacement of the requisite SP3-hybridized stereogenic center found at the 5-position of the oxazolidinone with a nitrogen atom. The synthesis and antibacterial activity of three such ring systems, the benzisoxazolinones, pyrroles, and isoxazolinones is described. (C) 2004 Elsevier Ltd. All rights reserved.
WO2007/64842
申请人:——
公开号:——
公开(公告)日:——
HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES